Revolution Medicines gets approval for daraxonrasib in metastatic pancreatic cancer
Regulators approved daraxonrasib for patients with metastatic pancreatic adenocarcinoma, according to the report. Revolution Medicines is described as having received the landmark approval of its pancreatic cancer pill late last month.